évolis

hair loss products available for purchase at evolisproducts.com.au

Click here to view »

Annual Report

2013 Annual Report

 

Click here to read »

Welcome to Cellmid


Cellmid Limited (ASX:CDY) is an Australian immuno-oncology company developing first in class antibodies against the novel target midkine (MK). 

Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the growth factor midkine (neurite growth-promoting factor 2). Midkine is an extensively validated therapeutic and diagnostic target in cancer, inflammation and auto-immune disorders. 

Cellmid is actively seeking partners to commercialise these significant intellectual property assets in cancer, ischemia, and inflammatory diseases.

 

Cellmid's Partners

Latest News